Research and Development Investment and Royalty Agreement with Medipal Holdings
First written in FY2017-Q2. 8 of 12 entries say "Advanced", first in FY2018-Q2. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「In addition, in August 2025, we entered into a license agreement with the company covering the overseas commercialization of a drug candidate for GM2 gangliosidosis (development number: JR-479), as well as a joint development and commercialization agreement in Japan.」
The research and development investment and licensing relationship with Medipal was expanded to include overseas commercialization of JR-479 and joint development and commercialization in Japan. - FY2024Update to transaction amountAnnual report
「Development investment agreement License agreement 5,500」
The transaction amount for the current fiscal year under the development investment and license agreements with Medipal Holdings Corporation was ¥5.5 billion, up from ¥4.0 billion in the previous fiscal year. - FY2024-Q2AdvancedAnnual report
「In September 2023, the company concluded a license agreement with Medipal Holdings Corporation for commercialization outside Japan, as well as a joint development and commercialization agreement in Japan.」
The existing development investment and partnership relationship with Medipal Holdings Corporation progressed to a new contractual stage, comprising an overseas license for JR-446 and joint development and commercialization in Japan. - FY2023AdvancedAnnual report
「Medipal Holdings Corporation Development investment agreement License agreement 4,000」
Disclosed transaction amounts of ¥4.0 billion for the fiscal year under the development investment and license agreements with Medipal Holdings Corporation. In addition, the parties entered into a commercialization agreement for JR-471 and granted exclusive negotiation rights for the global commercialization of four ultra-rare disease treatments. - FY2021AdvancedAnnual report
「Development investment agreement 2,000」
Disclosed transaction amounts of ¥2.0 billion for the fiscal year under the development investment agreement with Medipal Holdings Corporation, and ¥1.915 billion in advances received at the fiscal year-end. - FY2019RestatedAnnual report
「We have entered into agreements with Medipal Holdings Corporation under which Medipal Holdings Corporation will bear part of the research and development costs, we will pay royalties, and clinical development of various drug candidates will be conducted through a U.S. joint venture.」
Reconfirmed the framework of the agreements covering Medipal's partial funding of research and development costs, royalties, and clinical development through a U.S. joint venture. - FY2018-Q3AdvancedAnnual report
「To oversee the early-stage clinical development of JR-141 and JR-162 in the United States, we established the US joint venture JCR USA, Inc. with Medipal Holdings Co., Ltd. on 1 January this year. Going forward, we plan to consider the global expansion of our development portfolio from the US joint venture.」
Established a joint venture to conduct clinical development in the United States for JR-141 and JR-162, as part of making the development investment and business partnership with Medipal more concrete. - FY2018-Q2AdvancedAnnual report
「The Company has entered into development investment agreements with its largest shareholder, メディパルホールディングス, concerning multiple products under development. The parties have also agreed to conduct clinical development of various drug candidates through a joint venture to be established in the United States and to pursue broader business collaboration.」
In addition to the existing development investment agreement covering 2 products, the parties agreed to clinical development through a U.S. joint venture and a broader business alliance. - FY2017-Q3RestatedAnnual report
「Amid this active research and development, in July last year the company entered into a new development investment agreement with メディパルホールディングス covering 2 products currently under research and development by the company.」
Reiterates the development investment agreement covering 2 products with MEDIPAL HOLDINGS CORPORATION. No new agreement or changes to the agreement's terms are disclosed. - FY2017-Q2First statedAnnual report
「MEDIPAL HOLDINGS CORPORATION bears part of the R&D costs, and the Company pays royalties. In July this year, the Company also entered into a new development investment agreement with MEDIPAL HOLDINGS CORPORATION covering 2 products under development by the Company.」
Entered into an agreement under which MEDIPAL HOLDINGS CORPORATION bears part of the R&D costs and the Company pays royalties at a specified rate. The agreement covers 2 products under development, and remains in effect until royalty payments end.